Compare
Icon PLC vs Iqvia Holdings Inc. vs Charles River Laboratories International, Inc. vs Medpace Holdings, Inc.
| Latest fiscal year | Icon PLC ICLR | Iqvia Holdings Inc. IQV | Charles River Laboratories International, Inc. CRL | Medpace Holdings, Inc. MEDP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-27 | 2025-12-31 |
| Revenue | $8.25B | $16.31B | $4.02B | $2.53B |
| Revenue growth (YoY) | +0.8% | +5.9% | -0.9% | +20.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | 5.4% | 13.4% | 0.6% | 21.1% |
| Net margin | 2.8% | 8.3% | -3.5% | 17.8% |
| Net income | $229.34M | $1.36B | -$142.16M | $451.12M |
| EPS (Diluted) | $2.90 | $7.84 | -$2.91 | $15.28 |
| Operating cash flow | $1.04B | $2.65B | $737.65M | $713.22M |
| Free cash flow | $861.99M | $2.05B | $518.49M | $681.87M |
| Cash & equivalents | $647.29M | $1.98B | $213.77M | $497.05M |
| Total assets | $16.27B | $29.94B | $7.14B | $1.98B |
| Total liabilities | $7.08B | $23.31B | $3.92B | $1.52B |
| Shareholders' equity | $9.19B | $6.63B | $3.17B | $459.07M |
| Return on year-end equity | 2.5% | 20.5% | -4.5% | 98.3% |
| Shares outstanding | 76.57M | 169.60M | 49.22M | 28.37M |
Revenue, most recent five fiscal years
| Fiscal year | Icon PLC | Iqvia Holdings Inc. | Charles River Laboratories International, Inc. | Medpace Holdings, Inc. |
|---|---|---|---|---|
| Latest | $8.25B Ended 2025-12-31 | $16.31B Ended 2025-12-31 | $4.02B Ended 2025-12-27 | $2.53B Ended 2025-12-31 |
| 1 year earlier | $8.19B Ended 2024-12-31 | $15.40B Ended 2024-12-31 | $4.05B Ended 2024-12-28 | $2.11B Ended 2024-12-31 |
| 2 years earlier | $8.05B Ended 2023-12-31 | $14.98B Ended 2023-12-31 | $4.13B Ended 2023-12-30 | $1.89B Ended 2023-12-31 |
| 3 years earlier | $7.74B Ended 2022-12-31 | $14.41B Ended 2022-12-31 | $3.98B Ended 2022-12-31 | $1.46B Ended 2022-12-31 |
| 4 years earlier | $5.48B Ended 2021-12-31 | $13.87B Ended 2021-12-31 | $3.54B Ended 2021-12-25 | $1.14B Ended 2021-12-31 |